- Home
- COCH vs KALA Comparison
COCH vs KALA Comparison
Compare COCH & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- KALA
- Stock Information
- Founded
- COCH 1995
- KALA 2009
- Country
- COCH United States
- KALA United States
- Employees
- COCH N/A
- KALA N/A
- Industry
- COCH Blank Checks
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- KALA Health Care
- Exchange
- COCH Nasdaq
- KALA Nasdaq
- Market Cap
- COCH 25.2M
- KALA 26.2M
- IPO Year
- COCH N/A
- KALA 2017
- Fundamental
- Price
- COCH $1.29
- KALA $18.62
- Analyst Decision
- COCH Strong Buy
- KALA Strong Buy
- Analyst Count
- COCH 2
- KALA 3
- Target Price
- COCH $9.25
- KALA $25.00
- AVG Volume (30 Days)
- COCH 789.8K
- KALA 266.2K
- Earning Date
- COCH 07-31-2025
- KALA 11-11-2025
- Dividend Yield
- COCH N/A
- KALA N/A
- EPS Growth
- COCH N/A
- KALA N/A
- EPS
- COCH N/A
- KALA N/A
- Revenue
- COCH $222,000.00
- KALA N/A
- Revenue This Year
- COCH $4.27
- KALA N/A
- Revenue Next Year
- COCH $23.37
- KALA N/A
- P/E Ratio
- COCH N/A
- KALA N/A
- Revenue Growth
- COCH N/A
- KALA N/A
- 52 Week Low
- COCH $1.06
- KALA $2.92
- 52 Week High
- COCH $3.99
- KALA $18.89
- Technical
- Relative Strength Index (RSI)
- COCH 46.37
- KALA 86.37
- Support Level
- COCH $1.23
- KALA $13.14
- Resistance Level
- COCH $1.37
- KALA $15.66
- Average True Range (ATR)
- COCH 0.09
- KALA 1.56
- MACD
- COCH 0.02
- KALA 0.58
- Stochastic Oscillator
- COCH 69.70
- KALA 97.40
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.